The vagus nerve and autonomic imbalance in heart failure: Past, present, and future

Heart Failure Reviews

Volumn 16, Issue 2, 2011, Pages 97-99

  Hauptman, Paul J ^a,c   Mann, Douglas L ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC SYSTEM; AUTONOMIC DYSFUNCTION; CARDIAC RESYNCHRONIZATION THERAPY; DEFIBRILLATION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; MEDICAL RESEARCH; PARASYMPATHETIC TONE; PATHOGENESIS; PATIENT SAFETY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; SYMPATHETIC TONE; THERAPY EFFECT; VAGUS NERVE; VAGUS NERVE STIMULATION;

AUTONOMIC NERVOUS SYSTEM; DISEASE PROGRESSION; HEART FAILURE; HUMANS; RENIN-ANGIOTENSIN SYSTEM; VAGUS NERVE; VAGUS NERVE STIMULATION;

EID: 79951578116     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-010-9222-2     Document Type: Short Survey

References (26)

1. Anonymous (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325:293-302
2. M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM Gilbert NH Shusterman 1996 The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US carvedilol heart failure study group N Engl J Med 334 1349 1355 1:CAS:528:DyaK28Xjs1Wjtbw%3D 10.1056/NEJM199605233342101 8614419 (Pubitemid 26152713)
3. M Jessup WT Abraham DE Casey AM Feldman GS Francis TG Ganiats MA Konstam DM Mancini PS Rahko MA Silver LW Stevenson CW Yancy 2009 Writing on behalf of the 2005 guideline update for the diagnosis and management of chronic heart failure in the adult writing committee. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines Circulation 119 1977 2016 10.1161/CIRCULATIONAHA.109. 192064 19324967
4. JG Cleland JC Daubert E Erdmann N Freemantle D Gras L Kappenberger L Tavazzi 2005 The effect of cardiac resynchronization on morbidity and mortality in heart failure N Engl J Med 352 1539 1549 1:CAS:528:DC%2BD2MXjtFGnsLo%3D 10.1056/NEJMoa050496 15753115 (Pubitemid 40517094)
5. ICD registry 2010 http://www.ncdr.com/webncdr/ICD/default.aspx. Accessed 1 Dec 2010
6. JR Teerlink M Metra GM Felker P Ponikowski AA Voors BD Weatherley A Marmor A Katz J Grzybowski E Unemori SL Teichman G Cotter 2009 Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study Lancet 373 1429 1439 1:CAS:528:DC%2BD1MXltVCqtbk%3D 10.1016/S0140-6736(09)60622- X 19329178
7. de Ferrari GM, Crijns HJGM, Borggrefe M, Milasinovic G, Smid J, Zabel M, Gavazzi A, Sanzo A, Kuschyk J, Raspopovic S, Klein H, Swedberg K, Schwartz PJ (2010) Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J. doi: 10.1093/eurheartj/ehq391
8. JN Cohn G Tognoni 2001 The effect of the angiotensin receptor blocker valsartan on morbidity and mortality in heart failure N Engl J Med 345 1667 1675 1:CAS:528:DC%2BD3MXovFKjtLc%3D 10.1056/NEJMoa010713 11759645 (Pubitemid 33126822)
9. JJ McMurray J Ostergren K Swedberg CB Granger P Held EL Michelson B Olofsson S Yusuf MA Pfeffer 2003 Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 767 771 1:CAS:528:DC%2BD3sXntVGktLo%3D 10.1016/S0140-6736(03)14283-3 13678869 (Pubitemid 37093916)
10. H Krum A Maggioni 2010 Renin inhibitors in chronic heart failure: the aliskiren observation of heart failure treatment study in context Clin Cardiol 33 536 541 10.1002/clc.20828 20842736
11. DL Mann JJ McMurray M Packer K Swedberg JS Borer WS Colucci J Djian H Drexler A Feldman L Kober H Krum P Liu M Nieminen L Tavazzi DJ van Veldhuisen A Waldenstrom M Warren A Westheim F Zannad T Fleming 2004 Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) Circulation 109 1594 1602 1:CAS:528:DC%2BD2cXisFOqtr4%3D 10.1161/01.CIR.0000124490.27666.B2 15023878 (Pubitemid 38451714)
12. DL Mann MA Acker M Jessup HN Sabbah RC Starling SH Kubo 2007 Clinical evaluation of the CorCap cardiac support device in patients with dilated cardiomyopathy Ann Thorac Surg 84 1226 1235 10.1016/j.athoracsur.2007.03.095 17888974 (Pubitemid 47417855)
13. MM Borggrefe T Lawo C Butter H Schmidinger M Lunati B Pieske AR Misier A Curnis D Bocker A Remppis J Kautzner M Stuhlinger C Leclerq M Taborsky M Frigerio M Parides D Burkhoff G Hindricks 2008 Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure Eur Heart J 29 1019 1028 10.1093/eurheartj/ehn020 18270213 (Pubitemid 351844673)
14. DH Birnie ASL Tang 2006 The problem of non-response to cardiac resynchronization therapy Curr Opin Cardiol 21 20 26 10.1097/01.hco.0000198983. 93755.99 16355025 (Pubitemid 43194328)
15. JF Beshai RA Grimm SF Nagueh JH Baker SL Beau SM Greenberg LA Pires PJ Tchou 2007 For the RethinQ study investigators. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes N Engl J Med 357 2461 2471 1:CAS:528:DC%2BD2sXhsVemtbfO 10.1056/NEJMoa0706695 17986493 (Pubitemid 350272785)
16. B Olshansky N Sabbah PJ Hauptman WS Colucci 2008 The parasympathetic nervous system and heart failure: pathophysiology and implications for therapy Circulation 118 863 871 10.1161/CIRCULATIONAHA.107.760405 18711023
17. Schwartz PJ, de Ferrari GM (2011) Sympathetic-parasympathetic interaction in health and disease: abnormalities and relevance in heart failure. Heart Fail Rev. doi: 10.1007/s10741-010-9179-1
18. Chapleau MW, Sabharwal R (2011) Methods of assessing vagus nerve activity and reflexes. Heart Fail Rev. doi: 10.1007/s10741-010-9174-6
19. Bibevski S, Dunlap M (2011) Evidence for impaired vagal nerve activity in heart failure. Heart Fail Rev. doi: 10.1007/s10741-010-9190-6
20. Li W, Olshansky B (2011) Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation. Heart Fail Rev. doi: 10.1007/s10741-010-9184-4
21. Zhang Y, Mazgalev T (2011) Arrhythmias and vagus nerve stimulation. Heart Fail Rev. doi: 10.1007/s10741-010-9178-2
22. Cohen ML, Georgievskaya Z (2011) Histopathology of the stimulated vagus nerve: primum non nocere. Heart Fail Rev. doi: 10.1007/s10741-010-9182-6
23. Sabbah HN (2011) Vagus nerve stimulation in experimental heart failure. Heart Fail Rev. doi: 10.1007/s10741-010-9209-z
24. PJ Schwartz GM de Ferrari A Sanzo M Landolina R Rordorf C Raineri C Campana M Revera N Ajmone-Marsan L Tavazzi A Odero 2008 Long term vagal stimulation in patients with advanced heart failure: first experience in man Eur J Heart Fail 10 884 891 10.1016/j.ejheart.2008.07.016 18760668
25. Desai M, Watanabe M, Laddu A, Hauptman PJ (2011) Pharmacologic modulation of parasympathetic activity in heart failure. Heart Fail Rev. doi: 10.1007/s10741-010-9195-1
26. de Ferrari GM, Schwartz PJ (2011) Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future. Heart Fail Rev. doi: 10.1007/s10741-010-9216-0